secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-10-09T21:25:16+00:00
Accession:  0001683168-26-007758
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Sunshine Biopharma prices and closes $6.0M public offering, with up to $14.4M more if Series D warrants exercised
--------------------------------------------------------------------------------

- On October 8, 2026, Sunshine Biopharma entered a placement agent agreement with Aegis Capital Corp. for a best-efforts public offering of Common Units and Pre-Funded Units.
- The offering priced at $0.55 per Common Unit and $0.54999 per Pre-Funded Unit; gross proceeds were about $6.0 million before fees and expenses.
- The offering included 10,509,082 Common Units and 400,000 Pre-Funded Units, each with two Series D warrants exercisable at $0.66 and expiring five years after issuance.
- The closing occurred October 9, 2026; the Series D warrants could raise up to approximately $14.4 million if fully exercised for cash.
- Aegis Capital Corp. received a 7% placement agent fee and a 1% non-accountable expense allowance; Sichenzia Ross Ference Carmel LLP and Kaufman & Canoles, P.C. acted as counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007758/0001683168-26-007758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007758/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer